Regulus - RGLS Expected earnings per share growth for next year
Strict FDA oversight and miRNA patent protection create high barriers to entry for competitors. The forward EPS trend clearly illustrates market expectations, where 0.00 shows the level of this metric. The orphan drug status of future medications will provide Regulus Therapeutics (RGLS) with pricing power, while the monetization of its RNA platform through partnerships with tech giants guarantees stable milestone payments.
regulusrx.com - analytical breakdowns and key metrics (RGLS)
- stock quotes and analyst forecast:
- issuer market value details:
- book capitalization information:
- debt burden and liquidity indicators:
Debt to Equity Regulus Therapeutics|RGLS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Regulus Therapeutics Inc.|RGLS - Company Aggregate Debts|Debt to Book Capitalization Ratio Regulus Therapeutics|RGLS - Long-Term Liabilities|Company Short-Term Debts Regulus Therapeutics|Quick Liquidity Indicator regulusrx.com
- earnings and valuation multiples information:
RGLS - Net Profit|Future Profit Regulus Therapeutics|RGLS - Market Price to Net Income Ratio|Forward P/E Multiple Regulus Therapeutics|RGLS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Regulus Therapeutics|RGLS - Operating profit before deduction of amortization|Earnings per share for the last twelve months Regulus Therapeutics|RGLS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months regulusrx.com|RGLS - Earnings per share increase in current year|Earnings growth forecast for next year Regulus Therapeutics
Basic company analysis:RGLS, Regulus Therapeutics Inc
For Regulus Therapeutics (RGLS), the estimated growth in net earnings per share for the coming year reflects market rates on the success of clinical trials for polycystic kidney disease therapy. This indicator measures the trend of expected returns, allowing investors to assess the risk of overpaying for the asset based on the efficiency of R&D expenditures and the company's current liquidity levels.
Who Regulus Therapeutics competes with
Expected earnings per share growth for next year TEM|QGEN: Expected earnings per share trend next year|Expected earnings per share growth for next year IONS (Ionis Pharmaceuticals)|Projected earnings per share increase next year RGEN|Earnings growth forecast for next year RNA (Avidity Biosciences, Inc.)|Expected earnings per share trend next year CRSP|Sema4 - Earnings growth forecast for next year|Expected net earnings per share growth next year Ultragenyx Corp|Beam Therapeutics Inc. (BEAM) - Net earnings per share growth forecast for next year|sarepta.com - Expected earnings per share trend next year|TWST (Twist Bioscience, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year 10x Genomics Inc|Net earnings per share growth forecast for next year Intellia (NTLA)|STOK: Net earnings per share change forecast for next year|Earnings growth forecast for next year BLFS (BioLife Solutions, Inc.)|wavelifesciences.com (WVE) - Expected net earnings per share growth next year|MAZE: Expected earnings per share growth for next year|SION - Earnings growth forecast for next year|PRME (Prime Medicine Corp) - Expected earnings per share growth for next year|TSHA: Projected earnings per share increase next year|QURE (uniQure N.V.) - Earnings growth forecast for next year|meiragtx.com (MGTX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RGNX|Expected earnings per share growth for next year Solid Biosciences Inc SLDB|Net earnings per share growth forecast for next year Ocugen Corp OCGN|Consensus forecast of earnings per share growth for next year PacBio Corp (PACB)|BNTC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year DSGN (designtx.com)|RCKT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year 4DMT FDMT|Net earnings per share growth forecast for next year Lexeo Therapeutics Inc.|Net earnings per share growth forecast for next year KRRO|Net earnings per share growth forecast for next year Editas Medicine, Inc. (EDIT)|Consensus forecast of earnings per share growth for next year silence-therapeutics.com|Earnings growth forecast for next year PRQR (ProQR Therapeutics)|CDXS: Projected earnings per share growth rate for next year|SGMO - Net earnings per share growth forecast for next year|NAUT (Nautilus Biotechnology) - Projected earnings per share growth rate for next year|MGX: Earnings growth forecast for next year|Precision BioSciences Inc. (DTIL) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Generation Bio Co|BOLD: Expected earnings per share trend next year|Earnings growth forecast for next year XCUR|IMNN - Expected net earnings per share growth next year|Earnings growth forecast for next year PHIO (Phio Pharmaceuticals Corp.)|Net earnings per one share growth forecast for next year Mustang Bio Inc|RNAZ: Expected earnings per share growth for next year|BNGO - Earnings growth forecast for next year|Applied DNA (APDN) - Net earnings per share growth forecast for next year|BLUE (bluebird bio, Inc) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year IPA|Earnings growth forecast for next year omegatherapeutics.com|Net earnings per share growth forecast for next year Singular Genomics (OMIC)|Consensus forecast of earnings per share growth for next year Syros Pharmaceuticals Inc.|Codex DNA - Expected earnings per share growth for next year|Expected earnings per share trend next year TCON|UBX: Expected earnings per share growth for next year
